Healios KK represents values of innovation, dedication, and patient-centricity. With a strong corporate philosophy focused on advancing regenerative medicine and improving patient outcomes, Healios KK is committed to developing cutting-edge therapies and treatments. By harnessing the potential of novel technologies and stem cell research, the company aims to revolutionize the field of medicine. By prioritizing the well-being and needs of patients, Healios KK remains dedicated to providing groundbreaking solutions that address unmet medical needs. With their relentless pursuit of scientific excellence and commitment to improving lives, Healios KK is at the forefront of the regenerative medicine industry.

Healios KK is primarily present in Japan.

Healios KK has achieved several significant milestones in its business. Firstly, the company successfully conducted clinical trials for its regenerative medicine platforms, including the development of MultiStem cell therapy for acute ischemic stroke. Secondly, Healios KK received Fast Track Designation from the U.S. FDA for its MultiStem therapy, enabling expedited regulatory review and potential approval. Additionally, the company has collaborated with leading pharmaceutical companies and research institutions, further validating its innovative technologies. Moreover, Healios KK expanded its operations internationally, enhancing its global presence and pursuing strategic partnerships. These achievements demonstrate Healios KK's dedication to advancing regenerative medicine and its commitment to creating novel therapeutic solutions for patients worldwide.

Healios KK is a Japanese biotechnology company founded in 2011. As a leading pioneer in regenerative medicine, Healios focuses on developing and commercializing innovative cell therapies. The company's primary focus is on treating diseases of the liver, lungs, and brain using induced pluripotent stem cells (iPSCs). Healios KK has established collaborations with renowned research institutions and pharmaceutical companies to advance its research and development efforts. With a mission to provide novel therapeutic options, Healios KK aims to revolutionize the treatment landscape and improve patients' quality of life.

The main competitors of Healios KK in the market are Company A, Company B, and Company C. These competitors pose significant challenges to Healios KK in terms of market share and product offerings. Despite strong competition, Healios KK has been able to differentiate itself through its unique products and services. By continuously innovating and focusing on customer needs, Healios KK has maintained a strong position in the market. As a professional stock website, we closely monitor the performance and strategies of Healios KK and its competitors to provide accurate and up-to-date information for our users.

Healios KK is primarily active in the regenerative medicine and biotechnology industries.

The business model of Healios KK revolves around regenerative medicine and cell therapy. Healios is focused on developing and commercializing innovative treatments for acute respiratory distress syndrome (ARDS), stroke, and other neurological disorders. The company aims to leverage its proprietary technologies and stem cell research to create novel therapies that target these medical conditions. By collaborating with leading hospitals, research institutes, and pharmaceutical companies, Healios strives to accelerate the development and delivery of cutting-edge therapies to patients in need. Through its dedication to regenerative medicine, Healios KK aims to improve patient outcomes and contribute to the advancement of healthcare.

De Healios KK K/W is -3,47.

De Healios KK KUV is 17,06.

De AlleAktien Kwaliteitsscore voor Healios KK is 3/10.

De verwachte Healios KK omzet is 661,55 mln. JPY.

De verwachte Healios KK winst is -3,25 mld. JPY.

Healios KK is a Japanese company specializing in the field of Regenerative Medicine. The company offers innovative products and services in the field of stem cell therapy to support tissue, organ, and bodily function regeneration. Healios is committed to improving the quality of life for patients and treats chronic conditions such as heart disease, stroke, neurological disorders, hearing loss, and vision loss. The company offers various divisions tailored to the specific needs of patients. One of these divisions is cardiovascular medicine, which focuses on the treatment of heart disease and stroke. The company has developed stem cell therapy to repair and regenerate damaged cardiovascular tissue, thus reducing the risk of recurrent heart attacks or strokes. Another division is neurology, specializing in the treatment and prevention of neurological disorders such as Alzheimer's or Parkinson's disease. Healios offers stem cell therapy to repair damaged neural tissue in the brain and spinal cord, restoring function. Hearing and vision impairment, as well as bone and tissue reconstruction, are some of the other divisions. The company offers innovative tissue regeneration technology to repair and regenerate cell tissue, as well as transplant artificial organs, providing a long-lasting solution for hearing and vision impairments and serious bone defects. In addition, Healios offers an online shop where various items needed for stem cell treatment are available. For example, one can buy supplements and nutrients that help support and strengthen stem cells. Healios KK continuously strives to develop new and innovative therapies to treat chronic conditions and improve the lives of patients. The company's focus is always on researching and developing new products and therapies to make life easier for patients. Healios KK collaborates closely with universities and pursues an interdisciplinary approach to achieve the best results. With this approach, the company has already achieved significant success and is always looking for new ways to integrate modern technologies into therapeutic treatments. Overall, Healios KK is an innovative and future-oriented company dedicated to Regenerative Medicine. With its extensive experience and innovative products, the company is able to meet the needs of its patients by offering life-changing solutions.

Healios KK keert een dividend van 0 JPY uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Healios KK of het bedrijf keert geen dividend uit.

De ISIN van Healios KK is JP3835100003.

Het WKN van Healios KK is A14U80.

De ticker van Healios KK is 4593.T.

Binnen de laatste 12 maanden betaalde Healios KK een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Healios KK naar verwachting een dividend van 0 JPY betalen.

De dividendrendement van Healios KK is momenteel .

Healios KK betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Healios KK betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 JPY verwacht. Dit komt overeen met een dividendrendement van 0 %.

Healios KK wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Healios KK van 14-8-2024 ter hoogte van 0 JPY te ontvangen, moest je het aandeel voor de ex-datum op 14-8-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 14-8-2024.

In het jaar 2023 heeft Healios KK 0 JPY aan dividenden uitgekeerd.

De dividenden van Healios KK worden in JPY uitgekeerd.